



IFWO

RAW SEQUENCE LISTING

DATE: 09/29/2004

PATENT APPLICATION: US/10/698,073

TIME: 13:03:48

Input Set : A:\30775723.app

Output Set: N:\CRF4\09292004\J698073.raw

3 <110> APPLICANT: ROBINSON, CYNTHIA B.
 4 BALL, HOWARD A.
 6 <120> TITLE OF INVENTION: COMBINATION OF DEHYDROEPIANDROSTERONE OR
 7 DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTI-IGE
 8 ANTIBODY FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE
 9 PULMONARY DISEASE
 11 <130> FILE REFERENCE: 30775-723.201
 C--> 13 <140> CURRENT APPLICATION NUMBER: US/10/698,073
 14 <141> CURRENT FILING DATE: 2003-10-26
 16 <150> PRIOR APPLICATION NUMBER: 60/492,231
 17 <151> PRIOR FILING DATE: 2003-07-31
 19 <160> NUMBER OF SEQ ID NOS: 19
 21 <170> SOFTWARE: PatentIn Ver. 3.2
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 114
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Artificial Sequence
 28 <220> FEATURE:
 29 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant
 30 Humanized Monoclonal Antibody
 32 <400> SEQUENCE: 1
 33 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 34 1 5 10 15
 36 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Lys Pro Val Asp Gly Glu
 37 20 25 30
 39 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
 40 35 40 45
 42 Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Glu Ser Gly Val Pro Ser
 43 50 55 60
 45 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 46 65 70 75 80
 48 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His
 49 85 90 95
 51 Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
 52 100 105 110
 54 Thr Val
 58 <210> SEQ ID NO: 2
 59 <211> LENGTH: 114
 60 <212> TYPE: PRT
 61 <213> ORGANISM: Artificial Sequence
 63 <220> FEATURE:
 64 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant
 65 Humanized Monoclonal Antibody



RAW SEQUENCE LISTING

DATE: 09/29/2004

PATENT APPLICATION: US/10/698,073

TIME: 13:03:48

Input Set : A:\30775723.app

Output Set: N:\CRF4\09292004\J698073.raw

67 <400> SEQUENCE: 2

```

68 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
69   1           5           10           15
71 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Glu
72           20           25           30
74 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
75           35           40           45
77 Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Glu Ser Gly Val Pro Ser
78           50           55           60
80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
81  65           70           75           80
83 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His
84           85           90           95
86 Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
87           100          105          110

```

89 Thr Val

93 <210> SEQ ID NO: 3

94 <211> LENGTH: 114

95 <212> TYPE: PRT

96 <213> ORGANISM: Artificial Sequence

98 <220> FEATURE:

99 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant

100 Humanized Monoclonal Antibody

102 <400> SEQUENCE: 3

```

103 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
104   1           5           10           15
106 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Asp
107           20           25           30
109 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
110           35           40           45
112 Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Glu Ser Gly Val Pro Ser
113           50           55           60
115 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
116  65           70           75           80
118 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His
119           85           90           95
121 Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
122           100          105          110

```

124 Thr Val

128 <210> SEQ ID NO: 4

129 <211> LENGTH: 114

130 <212> TYPE: PRT

131 <213> ORGANISM: Artificial Sequence

133 <220> FEATURE:

134 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant

135 Humanized Monoclonal Antibody

137 <400> SEQUENCE: 4

```

138 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
139   1           5           10           15

```

RAW SEQUENCE LISTING

DATE: 09/29/2004

PATENT APPLICATION: US/10/698,073

TIME: 13:03:48

Input Set : A:\30775723.app

Output Set: N:\CRF4\09292004\J698073.raw

```

141 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Ser Ile Thr Ser Gly
142          20          25          30
144 Tyr Ser Trp Asn Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
145          35          40          45
147 Val Ala Ser Ile Lys Tyr Ser Gly Glu Thr Lys Tyr Asn Pro Ser Val
148          50          55          60
150 Lys Gly Arg Ile Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Phe Tyr
151 65          70          75          80
153 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
154          85          90          95
156 Ala Arg Gly Ser His Tyr Phe Gly His Trp His Phe Ala Val Trp Gly
157          100          105          110
159 Gln Gly
163 <210> SEQ ID NO: 5
164 <211> LENGTH: 114
165 <212> TYPE: PRT
166 <213> ORGANISM: Artificial Sequence
168 <220> FEATURE:
169 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant
170      Humanized Monoclonal Antibody
172 <400> SEQUENCE: 5
173 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
174 1          5          10          15
176 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Ser Ile Thr Ser Gly
177          20          25          30
179 Tyr Ser Trp Asn Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
180          35          40          45
182 Val Ala Ser Ile Thr Tyr Asp Gly Ser Thr Asn Tyr Asn Pro Ser Val
183          50          55          60
185 Lys Gly Arg Ile Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Phe Tyr
186 65          70          75          80
188 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
189          85          90          95
191 Ala Arg Gly Ser His Tyr Phe Gly His Trp His Phe Ala Val Trp Gly
192          100          105          110
194 Gln Gly
198 <210> SEQ ID NO: 6
199 <211> LENGTH: 218
200 <212> TYPE: PRT
201 <213> ORGANISM: Artificial Sequence
203 <220> FEATURE:
204 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant
205      Humanized Monoclonal Antibody
207 <400> SEQUENCE: 6
208 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
209 1          5          10          15
211 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Asp
212          20          25          30
214 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/698,073

DATE: 09/29/2004

TIME: 13:03:48

Input Set : A:\30775723.app

Output Set: N:\CRF4\09292004\J698073.raw

```

215          35          40          45
217 Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Glu Ser Gly Val Pro Ser
218          50          55          60
220 Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
221 65          70          75          80
223 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser His
224          85          90          95
226 Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
227          100          105          110
229 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
230          115          120          125
232 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
233          130          135          140
235 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
236 145          150          155          160
238 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
239          165          170          175
241 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
242          180          185          190
244 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
245          195          200          205
247 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
248          210          215
251 <210> SEQ ID NO: 7
252 <211> LENGTH: 451
253 <212> TYPE: PRT
254 <213> ORGANISM: Artificial Sequence
256 <220> FEATURE:
257 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant
258 Humanized Monoclonal Antibody
260 <400> SEQUENCE: 7
261 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
262 1          5          10          15
264 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Ser Ile Thr Ser Gly
265          20          25          30
267 Tyr Ser Trp Asn Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
268          35          40          45
270 Val Ala Ser Ile Thr Tyr Asp Gly Ser Thr Asn Tyr Asn Pro Ser Val
271          50          55          60
273 Lys Gly Arg Ile Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Phe Tyr
274 65          70          75          80
276 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
277          85          90          95
279 Ala Arg Gly Ser His Tyr Phe Gly His Trp His Phe Ala Val Trp Gly
280          100          105          110
282 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
283          115          120          125
285 Val Phe Pro Leu Ala Pro Ser Lys Ser Thr Ser Gly Gly Thr Ala
286          130          135          140

```

RAW SEQUENCE LISTING

DATE: 09/29/2004

PATENT APPLICATION: US/10/698,073

TIME: 13:03:48

Input Set : A:\30775723.app

Output Set: N:\CRF4\09292004\J698073.raw

```

288 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
289 145 150 155 160
291 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
292 165 170 175
294 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
295 180 185 190
297 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
298 195 200 205
300 Lys Pro Ser Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
301 210 215 220
303 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
304 225 230 235 240
306 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
307 245 250 255
309 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
310 260 265 270
312 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
313 275 280 285
315 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
316 290 295 300
318 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
319 305 310 315 320
321 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
322 325 330 335
324 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
325 340 345 350
327 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser
328 355 360 365
330 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Leu Ala Val Glu
331 370 375 380
333 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
334 385 390 395 400
336 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
337 405 410 415
339 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
340 420 425 430
342 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
343 435 440 445
345 Pro Gly Lys
346 450
349 <210> SEQ ID NO: 8
350 <211> LENGTH: 218
351 <212> TYPE: PRT
352 <213> ORGANISM: Artificial Sequence
354 <220> FEATURE:
355 <223> OTHER INFORMATION: Description of Artificial Sequence: Recombinant
356 Humanized Monoclonal Antibody
358 <400> SEQUENCE: 8
359 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/698,073

DATE: 09/29/2004

TIME: 13:03:49

Input Set : A:\30775723.app

Output Set: N:\CRF4\09292004\J698073.raw

L:13 M:270 C: Current Application Number differs, Replaced Current Application Number